Join our daily newsletter At The Bell to receive exclusive market insights
- NeuroScientific Biopharmaceuticals (NSB) is partnering with Linear Clinical Research to begin Phase 1 clinical trials with its lead drug candidate EmtinB
- This marks the first in-human study of EmtinB in up to 90 healthy volunteers, with the trial seeking to assess the drug’s safety and tolerability
- The company says the study will be used to support future Phase II trials in Alzheimer’s disease and multiple sclerosis
- NeuroScientific Biopharmaceuticals last traded at 36 cents on June 22
NeuroScientific Biopharmaceuticals (NSB) has partnered with Linear Clinical Research to begin Phase 1 clinical trials with its lead drug candidate EmtinB.
EmtinB is a compound that binds to surface-based cell receptors, stimulating neuroprotection, neuroregeneration and modulate neuroinflammation. The company says the treatment is safe and well tolerated at high concentrations and is able to penetrate the blood brain barrier.
Perth-based clinical research organisation, Linear, will assist with the first in-human study of EmtinB in healthy volunteers, with the trial seeking to assess the drug’s safety, tolerability and pharmacokinetics.
Up to 90 participants are set to be recruited, with multiple dose cohorts utilised. The study will then be used to support future Phase II trials in Alzheimer’s disease and multiple sclerosis.
“This partnership is a significant milestone for NeuroScientific and we are elated to be transitioning our R&D (research and development) program into first-in-human trials with another leading-edge, WA-based company in Linear Clinical Research,” NSB’s Managing Director, Matt Liddelow said.
“The trial is also a significant milestone for the advancement of EmtinB as a potential disease-modifying drug for a range of neurodegenerative conditions that currently lack such treatments, including Alzheimer’s disease and Multiple sclerosis.”
Additionally, NSB plans to undertake a Phase I trial of EmtinB in glaucoma patient, with the treatment administered by intravitreal delivery.
NeuroScientific Biopharmaceuticals last traded at 36 cents on June 22.
